Compare IMKTA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMKTA | NVCR |
|---|---|---|
| Founded | 1963 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Food Chains | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1994 | 2015 |
| Metric | IMKTA | NVCR |
|---|---|---|
| Price | $89.39 | $15.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.08 |
| AVG Volume (30 Days) | 133.1K | ★ 1.5M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,334,032,609.00 | $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $59.27 | $9.82 |
| 52 Week High | $95.62 | $18.92 |
| Indicator | IMKTA | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 44.45 |
| Support Level | $86.11 | $14.85 |
| Resistance Level | $89.76 | $15.19 |
| Average True Range (ATR) | 2.34 | 0.87 |
| MACD | -0.18 | -0.33 |
| Stochastic Oscillator | 39.47 | 34.89 |
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.